A Humanized Anti-Interleukin 6 Receptor Monoclonal Antibody, Tocilizumab, for the Treatment of Endometriosis in a Rat Model

Basit Öğe Kaydı
dc.contributor.authorTaşkın, Mine Islimye
dc.contributor.authorGungor, Aysenur Cakir
dc.contributor.authorAdali, Ertan
dc.contributor.authorYay, Arzu
dc.contributor.authorÖnder, Gözde Özge
dc.contributor.authorİnceboz, Ümit
dc.date.accessioned2025-01-27T20:50:20Z
dc.date.available2025-01-27T20:50:20Z
dc.date.issued2016
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjective: The aim of this study was to investigate the efficacy of anti-interleukin 6 (IL-6) therapy in the treatment of endometriosis in a rat model. Study Design: After the peritoneal implantation of autologous endometrial tissue, 22 Wistar female rats were divided to create 2 intervention groups: the tocilizumab group (n = 13) and the control group (n = 9). After measuring implant volume, saline was administered to the rats in the control group and 8 mg/kg tocilizumab was administered intraperitoneally to the rats in the tocilizumab-treated group every 2 weeks. After a 4-week treatment period, the volumes and histopathological properties of the implants were evaluated. A scoring system was used to evaluate the preservation of epithelia. Fibrosis score was assessed between the groups. Ectopic and eutopic endometrium were evaluated immunohistochemically for IL-6 and vascular endothelial growth factor (VEGF). Results: There was a significant difference between the volumes of implants before and after treatment in the tocilizumab group (P < .05). The posttreatment volumes of lesions were smaller in the tocilizumab group than in the control group. Histologic and fibrosis scores were lower in the tocilizumab group than in the control group. Immunoreactivity intensity for VEGF was significantly decreased in the tocilizumab group for ectopic and eutopic endometrium (P < .05). Interleukin 6 levels and endometrial thickness for ectopic and eutopic endometrium were similar between the groups. Conclusion: Tocilizumab treatment had a regressive effect on the endometriotic implants.
dc.identifier.doi10.1177/1933719115612134
dc.identifier.endpage669
dc.identifier.issn1933-7191
dc.identifier.issn1933-7205
dc.identifier.issue5
dc.identifier.pmid26566855
dc.identifier.startpage662
dc.identifier.urihttps://doi.org/10.1177/1933719115612134
dc.identifier.urihttps://hdl.handle.net/20.500.12428/25471
dc.identifier.volume23
dc.identifier.wosWOS:000374247700013
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Inc
dc.relation.ispartofReproductive Sciences
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectIL-6
dc.subjecttocilizumab
dc.subjectendometriosis
dc.subjectrat model
dc.titleA Humanized Anti-Interleukin 6 Receptor Monoclonal Antibody, Tocilizumab, for the Treatment of Endometriosis in a Rat Model
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu